Gary Herschman, Member of the Firm, co-presents “The Rise of Private Equity Partnerships with Cardiology Groups: What’s Going On and Why?” with Dana Jacoby, President and CEO of Vector Medical Group.
Approximately 400 specialty physician groups entered into strategic partnership transactions with health care investors during 2021, a 90 percent increase over prior years. Cardiology groups are the latest focus of health care investors, as there currently are six active platforms, which are expected to double over the next 12–18 months. As we have seen in other specialties, there is a premium value placed on early entrants to the market.
These partnerships can be very lucrative for cardiologists, but transactions are not right for every group. Before deciding if a transaction is right for their particular practice, cardiologists should explore and assess their practice’s current and future challenges, their individual goals and objectives, and the terms of a potential partnership. (And also strategies for terminating and unwinding any PSAs.)
- Why so many cardiology practices are exploring and entering into strategic investor transactions
- Why cardiology practices are so highly valued in this super-hot market
- The pros and cons of entering into these transactions and how to best protect the interests of physicians in both the short and long term
- How to unwind cardiology group professional services agreements (PSAs) with hospitals so that cardiologists subject to PSAs can benefit from these lucrative investor partnerships
Access the Recording and Materials
If you have any questions, please reach out to Lauren Maus.
Members of the media, please contact Piper Hall.